Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 7/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31684324 | 0.93 | BTK (0.41) | BTKEPHX2MMP1MMP9MMP13 | |
| SCHEMBL15913949 | 0.93 | BTK (0.41) | BTKEPHX2MMP1MMP9MMP13 | |
| SCHEMBL31684304 | 0.93 | BTK (0.41) | BTKEPHX2MMP1MMP9MMP13 | |
| SCHEMBL15913950 | 0.93 | BTK (0.41) | BTKEPHX2MMP1MMP9MMP13 | |
| SCHEMBL21903794 | 0.85 | CYP1A2 (0.38) | BTKEPHX2 | |
| SCHEMBL20645567 | 0.85 | BTK (0.41) | BTKEPHX2SRC | |
| SCHEMBL31125791 | 0.84 | BTK (0.41) | BTKEPHX2SRCABL1EGFR | |
| SCHEMBL25649309 | 0.84 | BTK (0.41) | BTKEPHX2SRCABL1EGFR | |
| SCHEMBL21903524 | 0.84 | EPHX2 (0.44) | BTKPIK3CAPRKDCMTOREPHX2 | |
| SCHEMBL21903828 | 0.83 | KMT2A (0.42) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885PIK3CA 34/4885PRKDC 71/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885PIK3CA 31/4885PRKDC 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.